Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAP3K5 | Q99683 | 13/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24185391 | 0.81 | NPC1 (0.41) | L3MBTL1ALDH1A1MAP3K5RETCDK2 | |
| SCHEMBL15147819 | 0.81 | MAP3K5 (0.60) | L3MBTL1ALDH1A1MAP3K5 | |
| SCHEMBL22474086 | 0.80 | MAP3K5 (0.48) | ALDH1A1MAP3K5RETCDK2ITK | |
| SCHEMBL23011962 | 0.80 | MAP3K5 (0.47) | ALDH1A1MAP3K5 | |
| SCHEMBL28512196 | 0.76 | MAP3K5 (0.52) | MAP3K5 | |
| SCHEMBL30686028 | 0.76 | MAP3K5 (0.52) | MAP3K5 | |
| SCHEMBL17454629 | 0.75 | MAP3K5 (0.50) | L3MBTL1ALDH1A1MAP3K5P2RX7RET | |
| SCHEMBL29749429 | 0.75 | MAP3K5 (0.60) | MAP3K5RETCDK2ITKMERTK | |
| SCHEMBL30853831 | 0.75 | MAP3K5 (0.50) | L3MBTL1ALDH1A1MAP3K5P2RX7RET | |
| SCHEMBL3658697 | 0.74 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117440723-A | Display device, display module and electronic equipment | 株式会社半导体能源研究所 | 2024-01-23 | — | — | CN | disclosed |
| US-11839144-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210217973-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | UNIV ARIZONA STATE (US) | 2021-07-15 | — | — | US | disclosed |
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20180226593-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-08-09 | — | — | US | disclosed |
| US-9941479-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9365614-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-06-14 | — | — | US | disclosed |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | PHARMASCIENCE INC. (CA) | 2014-11-13 | — | — | US | disclosed |
| US-8765681-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2014-07-01 | — | — | US | disclosed |
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| US-7579320-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-08-25 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-7547724-B2 | IAP BIR domain binding compounds | AEGERA THERPEUTICS, INC. | 2009-06-16 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
| US-20080014207-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2008-01-17 | — | — | US | disclosed |
| US-20070219140-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180226593-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | DPYD, DCTD, TYMP | L3MBTL1 1284/4885ALDH1A1 1020/4885MAP3K5 3927/4885 |
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | DPYD, DCTD, TYMP | L3MBTL1 1284/4885ALDH1A1 1020/4885MAP3K5 3927/4885 |
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | L3MBTL1 317/4885ALDH1A1 4074/4885MAP3K5 2079/4885 |
| US-20080014207-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | L3MBTL1 317/4885ALDH1A1 4074/4885MAP3K5 2079/4885 |
| US-20210217973-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | DPYD, DCTD, TYMP | L3MBTL1 1284/4885ALDH1A1 1020/4885MAP3K5 3927/4885 |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | L3MBTL1 1026/4885ALDH1A1 3868/4885MAP3K5 1704/4885 |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | BIRC2, BIRC7, BIRC5 | L3MBTL1 1788/4885ALDH1A1 4635/4885MAP3K5 1112/4885 |
| US-20070219140-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC8 | L3MBTL1 316/4885ALDH1A1 3967/4885MAP3K5 2284/4885 |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | BIRC5, XIAP, BIRC2 | L3MBTL1 462/4885ALDH1A1 3955/4885MAP3K5 1755/4885 |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | L3MBTL1 154/4885ALDH1A1 3380/4885MAP3K5 1406/4885 |
| US-11839144-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | DPYD, DCTD, TYMP | L3MBTL1 1284/4885ALDH1A1 1020/4885MAP3K5 3927/4885 |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | BIRC5, XIAP, BAX | L3MBTL1 540/4885ALDH1A1 3619/4885MAP3K5 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.